美国 · 通讯社与实时数据 · PR Newswire
Rakuten Medical Presents Long-Term Follow-up Results of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for R/M HNSCC at ESMO 2026
Median DOR of 44.3 months supports durability of response 4-year overall survival rate of 35.3% and median OS of 28.2 months suggest meaningful long-term survival Long-term…
在 PR Newswire 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.prnewswire.com)
